How Will the Gastrointestinal Stromal Tumor Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Gastrointestinal Stromal Tumor market size evolved in recent years?
The market size for gastrointestinal stromal tumors has seen a robust growth in the past few years. It is projected to increase from $1.28 billion in 2024 to $1.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors responsible for this growth during the historic period include heightened awareness and early diagnosis, the advent of targeted therapies, refinement of surgical methods, progression in personalized medicine, and advances in supportive care.
What are the predictions for the gaucher’s disease market size in the coming years?
Expectations are robust for significant expansion in the gastrointestinal stromal tumor market over the coming years. The market size is projected to reach $1.82 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is associated with continual advancements in research and drug development, an increase in patient-focused healthcare approaches, the incorporation of precision medicine into clinical practice, wider access to targeted therapies, and the extension of genomic profiling capabilities. Major trends to look out for during this forecasted timeline include growing partnerships in research and development, improvements in diagnostic technologies, collective research and clinical trials, augmented emphasis on early detection and diagnosis, and the investigations into combinations of therapies.
Get your gastrointestinal stromal tumor market report here!
What key factors are fueling the growth of the gastrointestinal stromal tumor market?
An increasing number of stomach cancer cases are anticipated to enhance the expansion of the gastrointestinal stromal tumor market. The term stomach cancer applies to the unchecked growth and multiplication of cancerous cells in the stomach’s lining. While gastrointestinal stromal tumors (GISTs) can develop in the stomach, they aren’t the same as stomach cancer. The probability of developing additional cancers, such as small bowel adenocarcinoma, increases when two distinct tumors converge and fuse into one in patients with GISTs. For instance, it’s projected by The American Cancer Society, a professional U.S.-based organization, that there will be roughly 26,890 new stomach cancer cases and 10,880 related fatalities in the U.S. for 2024, making up 1.5% of all new cancer diagnoses. Consequently, the rise in stomach cancer occurrence is contributing to the expansion of the gastrointestinal stromal tumor market. In the wake of the growing requirement for precision medicine, a boost in the gastrointestinal stromal tumor market is foreseen. Precision medicine is a medical treatment method that customizes healthcare choices, interventions, and therapies based on individual patient specifics such as genetic factors and lifestyle. Precision medicine application to gastrointestinal stromal tumors includes molecular profiling to detect particular mutations, guiding targeted therapies such as imatinib, enhancing treatment effectiveness, and reducing side effects through tailored interventions. As per a 2023 report by the Personalized Medicine Coalition (PMC), a non-profit organization located in the U.S., personalized medications made up 35% of the newly approved NMEs in 2021 and, with 12 new approvals in 2022, have consistently constituted at least a quarter of new drug approvals for the last eight years, indicating a notable rise from less than 10% ten years ago. As a result, the demand surge for precision medicine is stimulating the expansion of the gastrointestinal stromal tumor market.
How is the global gastrointestinal stromal tumor market divided into key segments?
The gastrointestinal stromal tumor market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users
Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp
Who are the key firms paving the way for growth in the gastrointestinal stromal tumor market?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.
Which trends are expected to transform the gastrointestinal stromal tumor market?
Major corporations in the gastrointestinal stromal tumor market are devising groundbreaking pharmaceuticals, such as QINLOCK (Ripretinib), to cater to a larger demographic, increase product sales, and enhance revenue streams. QINLOCK (Ripretinib) is a prescribed medication used to manage advanced gastrointestinal stromal tumor (GIST). For example, in January 2024, the US Food and Drug Administration (FDA), a federal agency based in the US, reported an increase in CDER novel drug approvals from 37 in 2022 to 55 in 2023. The CDER recognized 20 of the 55 newly approved drugs (36%) in 2023 as first-in-class.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248
What regions are contributing significantly to the growth of the gastrointestinal stromal tumor market?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Intratumoral Cancer Therapies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report
Solid Tumor Cancer Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report
Circulating Tumor Cells Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
